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Pulmonary colonization and infection of patients with cystic fibrosis by Mycobacterium spp. has recently been
recognized as a potentially important clinical problem. However, frequent contamination of mycobacterial
cultures by pseudomonads has hampered efforts to define the extent of this problem. This study was done to
evaluate current techniques and to establish a more efficient method of recovering mycobacteria from
respiratory secretions of patients with cystic fibrosis. Decontamination of respiratory specimens (n = 121) with
0.25% N-acetyl-L-cysteine and 1% sodium hydroxide (NALC-NaOH) was associated with a high rate of
pseudomonas overgrowth for both Lowenstein-Jensen slants (74%) and BacTec vials supplemented with
PANTA (polymyxin B [50 U/mll, amphotericin B [5 ,ug/ml], nalidixic acid [20 ig/mll, trimethoprim [5 jig/mll,
azlocillin [10 ,ug/ml]) (36%). This overgrowth limited recovery of mycobacteria to only 64% (9 of 14) of
specimens positive by smear for acid-fast bacilli (AFB). Decontamination of specimens (n = 441) with
NALC-NaOH, followed by 5% oxalic acid treatment, resulted in contamination of only 5% of Lowenstein-
Jensen slants and 3% ofBacTec vials. AFB were recovered from all 90 AFB smear-positive specimens following
the use of this decontamination technique. We recommend that respiratory secretions be decontaminated with
NALC-NaOH and oxalic acid to decrease the incidence of Pseudomonas aeruginosa overgrowth.
Mycobacteria are being recovered with what appears to be
increasing frequency from the respiratory tracts of patient
with cystic fibrosis (CF). Six previous studies have been
done to assess the recovery rate of mycobacteria from CF
patients. Wood et al. (16) isolated Mycobacterium tubercu-
losis from 2 of over 700 CF patients; M. fortuitum was
recovered from three additional patients. Boxerbaum (1)
recovered M. chelonae from 6 and M. fortuitum from 2 of
430 patients. Hoiby (7) reported that 2 of 70 CF patients had
a mycobacterium other than M. tuberculosis recovered over
a 1-year period. Hjelte et al. (6) recovered mycobacteria
from 6 of 54 CF patients. M. tuberculosis was recovered
from one patient, the M. avium complex was recovered from
three, and two patients had unidentified isolates of myco-
bacteria. Smith et al. (14), in cultures from 223 patients,
found seven that were positive for mycobacteria, including
three with M. tuberculosis, one each with M. chelonae and
M. fortuitum, and two with unidentified mycobacteria. Most
recently, we reported the recovery of mycobacteria, prima-
rily the M. avium complex, from 20% of 87 adult CF patients
at the University of North Carolina Hospitals (9).
Other organisms which colonize or infect the respiratory
tracts of CF patients greatly complicate the recovery of
mycobacteria. Pseudomonas aeruginosa is a particular
problem, because it is present in the respiratory tracts of
approximately 80% of CF patients (4) and selected isolates
can survive the most commonly used sputum decontamina-
tion method (0.25% N-acetyl-L-cysteine [NALC]-1%
NaOH) (9, 14). When P. aeruginosa survives NALC-NaOH
decontamination, it can result in overgrowth and liquefac-
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tion of Lowenstein-Jensen (LJ) slants (9, 14) and false
positive-readings in BacTec vials. We (9) and Smith et al.
(14) have both reported that bacterial overgrowth by P.
aeruginosa prevented isolation of mycobacteria from speci-
mens positive for acid-fast bacilli (AFB) by smear. In our
study, we found that 67 of 297 cultures (22.6%) were
overgrown by bacteria, primarily P. aeruginosa. Therefore,
it is important to optimize decontamination conditions to
recover mycobacteria from this patient population.
This study was initiated to evaluate current techniques
used to decontaminate respiratory secretions obtained from
CF patients. In phase one, a retrospective analysis, we
determined the contamination rate of CF specimens treated
with NALC-NaOH. We compared those findings with re-
sults from a prospective study (phase two) using NALC-
NaOH followed by 5% oxalic acid for decontamination. In
addition, we investigated whether supplementation of Bac-
Tec vials with additional antimicrobial agents would de-
crease contamination rates. Recovery of mycobacteria from
smear-positive and smear-negative patients was determined
following the use of each technique.
MATERIALS AND METHODS
Patient population. Specimens were obtained from approx-
imately 100 patients seen in the CF clinic, as well as from CF
inpatients, at the University of North Carolina Hospitals
between September 1990 and February 1992. Respiratory
specimens, including sputa, tracheal aspirates, and speci-
mens obtained by bronchoscopy, were sent to the clinical
laboratory for AFB smear and culture. A total of 562
specimens were studied: 121 specimens in phase one of the
study and 441 specimens in phase two. All specimens were
processed within 24 h of receipt.
Decontamination techniques. (i) NALC-NaOH. Respiratory
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specimens were combined with an equal volume of 0.5%
NALC-2% NaOH in a 50-ml screw-top conical tube and
vortexed for at least 20 s. After 15 min of room temperature
incubation, the specimen volume was brought to 50 ml with
sterile distilled water and the resulting mixture was centri-
fuged for 5 min at 4,500 x g. The supernatant was poured
off, leaving approximately 1 ml of the concentrated specimen
for inoculation of media and smear preparation.
(ii) NALC-NaOH-oxalic acid. Respiratory specimens were
decontaminated as described above. An equal volume of 5%
oxalic acid was added to the concentrated sediment. This
mixture was vortexed and allowed to incubate at room
temperature for 30 min, with vortexing every 10 min. The
specimen volume was brought to 50 ml with sterile distilled
water, and the mixture was centrifuged for 5 min at 4,500 x
g. The supernatant was decanted, leaving approximately 1
ml of the specimen. With pH paper, the specimen was
neutralized by addition of 4% NaOH to a pH of approxi-
mately 7 prior to inoculation of media (12).
Culture techniques. Each specimen was inoculated onto
two IJ slants (BBL, Cockeysville, Md.) and into one Bac-
Tec 7H12B vial (Becton Dickinson Diagnostic Instrument
Systems, Cockeysville, Md.). Slides were also prepared
from concentrated sediment and stained by the Truant
fluorochrome technique (15). BacTec vials were supple-
mented with PANTA (polymyxin B [50 U/ml], amphotericin
B [5 ,g/ml], nalidixic acid [20 ,ug/ml], trimethoprim [5
,ug/ml], azlocillin [10 ,ug/ml]) in accordance with manufac-
turer recommendations. One portion of this study compared
two different antibiotic supplementations of the BacTec
vials. The first consisted of regular supplementation of the
BacTec vials with PANTA, while in the second method the
BacTec vials were supplemented with both PANTA and 50
,ug of piperacillin per ml immediately prior to specimen
inoculation. LJ slants were examined once a week for 8
weeks. BacTec vials were monitored twice weekly for the
first 2 weeks and once a week for weeks 3 and 4.
Seeding experiments. Sputum specimens from 30 CF pa-
tients known to be negative for AFB were used for seeding
experiments. A cell suspension of M. avium was adjusted to
a no. 1 McFarland standard, and 0.1 ml of this suspension
was added for every 1.0-ml specimen volume. This was done
to ensure that each specimen received a standardized num-
ber of organisms which was sufficient to allow consistent
recovery. Each specimen was divided into three equal
aliquots and decontaminated by one of the following meth-
ods previously described: NALC-NaOH, oxalic acid, or
NALC-NaOH followed by oxalic acid.
Organism identification. Identification of rapidly growing
acid-fast organisms was performed by standard techniques
as outlined in reference 12. M. avium complex isolates were
identified by the Accuprobe technique (Gen Probe, San
Diego, Calif.) (5).
Identification and susceptibility testing of bacterial contam-
inants. Pseudomonas species were identified by standard
methods (3). Susceptibilities were determined by the Bauer-
Kirby method in accordance with National Committee for
Clinical Laboratory Standards disk diffusion standards for
aerobic bacteria (11).
RESULTS
In our laboratory, the standard NALC-NaOH method for
decontaminating respiratory secretions cultured for myco-
bacteria is used. In the initial phase of this study, 121
respiratory specimens from CF patients were decontami-
TABLE 1. Recovery of AFB from 121 CF respiratory specimens
decontaminated by NALC-NaOH (phase one results)
No. of isolates that were:
AFB smear AFB smear
positive negative
Li BacTec Li BacTec
M. avium complex 3 4 1 3
M. chelonae 4 5 0 1
Bacterial overgrowth 7a 5b 82C 38d
Negative 0 0 24 65
a All 7 of these isolates were P. aeruginosa.
b All 5 of these isolates were P. aeruginosa.
c All 82 of these isolates were P. aeruginosa.
d Thirty-four of these isolates were P. aeruginosa, and four were P.
cepacia.
nated by this method (Table 1). Of these, 89 (74%) LI slants
and 43 (36%) BacTec vials were contaminated. The bacterial
contaminants recovered included 85 isolates of P. aerugi-
nosa and 4 of P. cepacia. We were able to isolate mycobac-
teria from only 9 of 14 AFB smear-positive specimens.
Cultures from the other five specimens were overgrown with
P. aeruginosa. Mycobacteria were isolated from 4 of 107
AFB smear-negative specimens. The demonstration of such
high rates of contamination in these respiratory specimens
led to the examination of alternative decontamination meth-
ods.
Studies were designed to examine the recovery of myco-
bacteria from 30 seeded respiratory specimens obtained
from CF patients following the use of each of three decon-
tamination methods: treatment with NALC-NaOH alone,
oxalic acid alone, or NALC-NaOH followed by oxalic acid.
Oxalic acid treatment, alone and in combination with
NALC-NaOH, was used in these pilot studies because of its
reported ability to eliminate P. aeruginosa as a contaminant
from sputum specimens (12). Treatment with NALC-NaOH
alone resulted in the highest contamination rate, with 70%
(21 of 30) of IJ slants and 47% (14 of 30) of BacTec vials
growing P. aeruginosa. Oxalic acid treatment alone yielded
53% (16 of 30) contamination of LJ slants and 50% (15 of 30)
contamination of BacTec vials. Treatment of specimens with
NALC-NaOH followed by oxalic acid resulted in 13% (4 of
30) and 10% (3 of 30) contamination of IJ slants and BacTec
vials, respectively.
On the basis of these results, a total of 441 respiratory
specimens were treated with NALC-NaOH followed by
oxalic acid (Table 2). Of these, 20 (5%) of the IJ slants and
13 (3%) of the BacTec vials were contaminated with
TABLE 2. Recovery of AFB from 441 CF respiratory specimens
decontaminated by NALC-NaOH-oxalic acid (phase two results)
No. of isolates that were:
AFB smear AFB smear
positive negative
Li BacTec Li BacTec
M. avium complex 34 34 11 15
M. chelonae 56 56 12 13
Bacterial overgrowth 0 0 20a13'
Negative 0 0 308 310
a All 20 of these isolates were P. aeruginosa.
b All 13 of these isolates were P. aeruginosa.
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P. aeruginosa. No other contaminants were isolated. Myco-
bacteria were recovered from all 90 AFB smear-positive
specimens, as well as from 28 smear-negative specimens.
Although NALC-NaOH-oxalic acid treatment had a low
contamination rate in BacTec vials (3%), we determined
whether a change in antimicrobial supplementation of the
vials might reduce contamination further. A total of 54
isolates of P. aeruginosa were recovered from BacTec vials
despite the presence of the standard antibiotic supplementa-
tion (PANTA). Forty-two of the 54 isolates were available
for susceptibility testing by disk diffusion. Thirty-seven of
these isolates were recovered post NALC-NaOH decontam-
ination, and five were recovered post NALC-NaOH-oxalic
acid treatment. A total of 35 (83%) were susceptible to
piperacillin. Other susceptibilities were ceftazidime (66%),
colistin (69%), imipenem (69%), ticarcillin-clavulanic acid
(52%), tobramycin (36%), gentamicin (36%), amikacin
(33%), ciprofloxacin (36%), chloramphenicol (10%), and
trimethoprim-sulfamethoxazole (5%).
On the basis of these antibiograms, we supplemented the
PANTA-containing BacTec vials with piperacillin (50 p,g/
ml). These bottles were processed in parallel with bottles
containing PANTA alone. A total of 238 CF respiratory
specimens were studied, and all were initially decontami-
nated with NALC-NaOH-oxalic acid. Of these, 38 were
positive for mycobacteria. The BacTec vials supplemented
with PANTA detected all 38 positive specimens and had a
contamination rate of 3.3% (8 of 238). The vials containing
piperacillin detected only 22 of the 38 positives and had a
contamination rate of 1.7% (4 of 283). Of the 22 samples that
were positive in both vials, 9 became positive on the same
day. However, the remaining 13 were detected in the
PANTA-supplemented vials an average of 7 days prior to
those in vials supplemented with PANTA and piperacillin
(range, 3 to 29 days).
DISCUSSION
Several surveys have shown that mycobacteria are
present in the lungs of CF patients (1, 6, 7, 9, 14, 16). The
pathogenic role of mycobacteria other than M. tuberculosis
in the lung disease of these patients is not understood,
although (9, 10, 14) pathogenic, nontuberculous mycobacte-
rial pulmonary infection is clearly present in some patients.
To understand the role of these organisms in CF lung disease
more fully, accurate methods for detecting them are needed.
Further, the importance of identifying patients infected or
colonized with these organisms has increased, with lung
transplantation becoming a therapeutic option in this patient
population. Posttransplant immunosuppressive therapy in-
creases the risk for opportunistic infections, including my-
cobacterial infections (13). Colonized CF patients may be at
even greater risk for developing posttransplant mycobacte-
rial infection. Accurate identification of CF lung transplant
candidates who are infected or colonized with mycobacteria
is required for better definition and management of this
clinical problem.
The rate of recovery of mycobacteria from CF respiratory
secretions is greatly complicated by the presence of P.
aeruginosa in the respiratory tracts of approximately 80% of
CF patients. We and others (9, 14) have had difficulty
isolating mycobacteria from smear-positive specimens be-
cause of bacterial overgrowth, usually due to the mucoid
phenotype of P. aeruginosa. Because of this problem of
bacterial overgrowth, nonculture methods, such as staining
or molecular techniques, seem to be ideal. However, acid-
fast staining techniques are not useful in determining the
species of mycobacterium. They also are not as sensitive as
culture (12). Gene probes have been shown to identify
isolates of both M. tuberculosis and the M. avium complex
accurately (5, 8). However, this technique requires initial
isolation of the mycobacteria before identification and has
not proven useful in detecting these organisms directly in
clinical specimens (5). The polymerase chain reaction may
prove to be an ideal method for detecting mycobacteria
directly from patients' specimens, but technical difficulties in
specimen processing make this technique unreliable (2).
Therefore, detection and identification of mycobacteria in
respiratory secretions still require isolation of the organisms.
We investigated decontamination and culture approaches
which could improve the recovery of mycobacteria from
respiratory specimens of CF patients. The standard NALC-
NaOH method of decontamination resulted in bacterial
overgrowth in 74% of LJ slants and 36% of antibiotic-
supplemented BacTec vials. Modification of this technique
to include 30 min of incubation with 5% oxalic acid following
NALC-NaOH digestion resulted in contamination rates of
only 3% with BacTec vials and 5% with LI slants. We do not
attribute these lower contamination rates to the presence of
fewer specimens containing P. aeruginosa in the NALC-
NaOH-oxalic acid-treated group than in the NALC-NaOH-
treated group. All specimens were obtained from the same,
primarily adult, CF population, of whom approximately 70%
are chronically colonized with P. aeruginosa (data not
shown). Further, seeding studies yielded similar results. Our
attempts to reduce bacterial overgrowth further, by addition
of piperacillin to the PANTA-supplemented BacTec vials,
revealed that contamination was slightly decreased (3.3 to
1.7%). However, recovery rates of mycobacteria were re-
duced by addition of piperacillin, and time to detection was
delayed for many isolates. Therefore, addition of piperacillin
to PANTA-supplemented BacTec vials is not warranted.
Bacterial decontamination of respiratory specimens from
CF patients with NALC-NaOH-oxalic acid yielded an im-
pressive reduction in bacterial overgrowth and improved
recovery of mycobacteria from all acid-fast stain-positive
specimens, as well as a number of smear-negative speci-
mens. We recommend this decontamination technique for
isolation of acid-fast organisms from this microbiologically
complex patient population.
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